Pancreatic Cancer Research

ResearcherGeorgetown UniversityActive in the last 2 years

John Lindsay Marshall

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3449-2344; OpenAlex author ID A5061373605. Sources: ClinicalTrials.gov.

Their work

Papers
22 (first author 0, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper, 1 trial · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: 1 paper, 1 trial · 2024: 2 papers

Papers 22

  1. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locall… Co-author DOI 10.1007/s12029-023-00996-3↗
  2. Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC). Co-author DOI 10.1016/j.ijrobp.2023.09.015↗
  3. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Co-author DOI 10.1200/po.23.00152↗
  4. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  5. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. Co-author DOI 10.1158/1078-0432.ccr-22-0275↗
  6. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. Co-author DOI 10.1089/pancan.2020.0005↗
  7. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/esmoopen-2020-000942↗
  8. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1301↗
  9. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1089/pancan.2019.0003↗
  10. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer. Co-author DOI 10.1007/s12029-016-9909-2↗
  11. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the Unit… Last author DOI 10.1007/s12325-018-0784-z↗
  12. Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Co-author DOI 10.1016/j.cancergen.2018.11.001↗
  13. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Co-author DOI 10.1016/j.cancergen.2017.08.006↗
  14. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000118↗
  15. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1038/mt.2016.66↗
  16. Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic c… Co-author DOI 10.3892/ol.2016.4101↗
  17. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-015-2855-z↗
  18. Pancreatic cancer, treatment options, and GI-4000. Last author DOI 10.1080/21645515.2014.1004017↗
  19. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study. Co-author PMID 25276262↗
  20. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Co-author DOI 10.1186/1748-717x-8-44↗
  21. A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Co-author PMID 23112883↗
  22. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0020687↗

Trials 2

  1. Evaluating Novel Therapies in ctDNA Positive GI Cancers Principal investigator NCT05482516↗
  2. Maintenance Dovitinib for Colorectal and Pancreas Cancer Principal investigator NCT01888965↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aiwu Ruth He · 9 shared papers, 2014–2024 · strength 0.90
  2. Benjamin Adam Weinberg · 6 shared papers, 2014–2024 · strength 0.76
  3. Louis M. Weiner · 7 shared papers, 2015–2024 · strength 0.73
  4. Michael Jon Pishvaian · 9 shared papers, 2013–2020 · strength 0.64
  5. Keith Robert Unger · 4 shared papers, 2017–2024 · strength 0.51
  6. Emily R. Winslow · 2 shared papers, 2024 · strength 0.37
  7. Marcus Smith Noel · 2 shared papers, 2024 · strength 0.37
  8. Michael J. Hall · 3 shared papers, 2020–2022 · strength 0.31
  9. Wolfgang Michael Korn · 3 shared papers, 2020–2022 · strength 0.31
  10. Anthony Frank Shields · 3 shared papers, 2020–2022 · strength 0.31
  11. David B. Spetzler · 2 shared papers, 2022–2023 · strength 0.26
  12. Jimmy J. Hwang · 4 shared papers, 2014–2020 · strength 0.26
  13. Anton Wellstein · 4 shared papers, 2011–2018 · strength 0.25
  14. Philip A. Philip · 3 shared papers, 2012–2022 · strength 0.23
  15. Emil Lou · 2 shared papers, 2022 · strength 0.23
  16. Wafik S. El‐Deiry · 2 shared papers, 2020–2022 · strength 0.20
  17. Jonathan Robert Brody · 2 shared papers, 2019–2020 · strength 0.20
  18. Andreas Seeber · 2 shared papers, 2020–2022 · strength 0.19
  19. Florian Kocher · 2 shared papers, 2020–2022 · strength 0.19
  20. Alberto Puccini · 2 shared papers, 2020–2022 · strength 0.19
  21. Richard M. Goldberg · 2 shared papers, 2020–2022 · strength 0.19
  22. Heinz‐Josef Lenz · 2 shared papers, 2020–2022 · strength 0.19
  23. Nicole Libbey · 1 shared paper, 2024 · strength 0.18
  24. Marie Kate Gurka · 3 shared papers, 2013–2018 · strength 0.17
  25. Eveline E. Vietsch · 2 shared papers, 2017–2018 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.